The last ten days have seen OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) break their long bear run that has rocked them since March 2017.
With their price back then being at highs of over $3.5, the company took a significant hit from the share price dip which spiraled them down to below $.4. However, with each passing day, we seem to be drawing closer to their comeback.
The company closed up just under 10% on Tuesday with over 700,000 shares traded by the market close. Their current share price stands at $.478.
Despite the pullback that arose days before arriving at this price, OWCP seems to be back to its rising glory as exemplified by the chart below:
History of OWCP
OWC Pharmaceutical Research Corp was formed in 2008 and headquartered in Israel. It is involved in the research and development of Marianas based pharmaceutical and treatment for a variety of medical issues. The momentum is rapidly rising in the medical and recreational cannabis and legal marijuana industry and some American companies are investing capital in infrastructure and plant assets to expand operations, to introduce the newest product and capitalize on the intensifying market conditions.
OWCP is one of them.
OWC and Cannabis
OWC through its subsidiary, one world cannabis ltd, conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PSTD, and migraines OWCP is also developing unique delivery systems for the effective and dosage of medical cannabis.
All OWCP research is conducted at leading Israel hospitals and scientific institutions and led by well-renowned investigators. The company’s research division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids and cannabis-based products for the treatment of various medical conditions, while its consulting division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
In April last year, an Israel based research company engaged in the development of cannabinoid-based therapies announced that it had received an expression of interest from the scientific and medical communities worldwide as a result of its preliminary clinical efficacy tests results of its topical cream to treat psoriasis. This marked a significant stride for OWC as it had financed the research with a flurry of inquiries from researchers worldwide wishing to get more information about the cream and its availability in the market.
The company will release the final results after proper protocols and clinical data and the full BIO-DATA IP PROTECTION.
Finally, the company appointed Dr. Stanley Hirsch as it’s active chairman of the board of directors. Dr. Stanley brings with him a wealth of experience and will be pivotal to the creation and implementation of strategies brought forth by the company, and they move into the future.
Ingestible Cannabis Tablet
The company’s most recent development has come in the form of ingestible cannabis.
Back in October 2016, the company announced that they had achieved one of their milestones by completing the development of the proprietary oral disintegrating cannabis-enriched tablet dubbed the sublingual tablet. The tablet was meant to provide an alternative to non-smokers who needed to benefit from some of the medical benefits of cannabis.
The company used some advanced technology to ensure that this tablet worked optimally. First, the tablet allows for any dosage of cannabis to be ingested through the sublingual delivery mechanism: the direct absorption of the compounds into the patient’s bloodstream through the oral epithelial tissue. Through this, it skips the first pass through the liver and has a much faster response time than regular pills. Furthermore, with it being a tablet, the patients can safely and accurately monitor the doses as prescribed. This is impossible to do in the case of a smoker.
The tablet is mainly targeted at chronic pain patients suffering from diseases such as Fibromyalgia or neuropathic pain and PTSD patients.
Upon this backdrop, the company has already gone through the different stages of testing the tablet has finally received the go-ahead to carry out the safety study of the oral disintegrating tablet Israel Medical Cannabis Agency (MCA).
The study which is expected to commence in the second quarter of 2018 will see OWCP bring to light the downsides that may accrue from the use of the tablet. In the coming weeks, the study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital after which the company can begin testing the product. They hope that the tablet, just like other marijuana products is safe for human use and that they can bring it to market as soon as possible.
The above was seconded by their Director of Research and Regulatory Affairs, Dr. Yehuda Baruch who said:
“We greatly look forward to introducing this breakthrough tablet to the marketplace after completing our testing. The preliminary results with the Tablet have been promising and we are eager to provide patients suffering from debilitating chronic conditions with effective non-opioid solutions.”
Expectations at OWCP are high as are their chances for growth once this tablet is brought to market. The above tests will go a long way towards ensuring OWCP maintains its name and standing within the cannabis sector long into the future.
OCWP is on a growth path. With such advancements in their research and development, the company is proving to be a vital force in the cannabis industry. We expect this trend to continue long into the future. Growth is imminent for OWCP.
We will be updating our subscribers as soon as we know more. For the latest updates on OCWP, sign up below!
Disclosure: We have no position in OWCP and have not been compensated for this article.
Image courtesy of AIDSVaccine via Flickr